Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Reader Login
  Home Print this page Email this page Small font sizeDefault font sizeIncrease font size Users Online: 187  
Export selected to
Reference Manager
Medlars Format
RefWorks Format
BibTex Format
  Citation statistics : Table of Contents
   2012| September-December  | Volume 11 | Issue 3  
    Online since November 10, 2012

  Archives   Previous Issue   Next Issue   Most popular articles   Most cited articles
Hide all abstracts  Show selected abstracts  Export selected to
  Cited Viewed PDF
Standard Operating Procedure for Prospective Individualised Dosimetry for [131] I-rituximab Radioimmunotherapy of Non-Hodgkin's Lymphoma
Phillipe J Calais, J Harvey Turner
September-December 2012, 11(3):110-116
DOI:10.4103/1450-1147.103409  PMID:23372448
Radioimmunotherapy (RIT) is an attractive therapy for non-Hodgkin's lymphoma (NHL) as it allows targeted tumor irradiation which provides a cytotoxic effect significantly greater than that of the immune-mediated effects of a non-radioactive, or 'cold', antibody alone. Anti-CD20 antibodies such as rituximab are ideal for RIT, as not only is it easily iodinated, but the CD20 antigen is found on more than 95% of B-cell NHL. A standard operating procedure (SOP) has been formulated for personalized prospective dosimetry for safe, effective outpatient 131 I-rituximab RIT of NHL. Over five years, experience of treatment of outpatients with 131 I-rituximab was analyzed with respect to critical organ radiation dose in patients and radiation exposure of their carers. This radiation safety methodology has been refined; and offers the potential for safe, practical application to outpatient 131 I-rituximab RIT of lymphoma in general and in developing countries in particular. Given endorsement and sanction of this SOP by local regulatory authorities the personalized dosimetry paradigm will facilitate incorporation of RIT into the routine clinical practice of therapeutic nuclear oncology worldwide.
  4 3,609 585
Standard Operating Procedure for In-house Preparation of 131 I-rituximab for Radioimmunotherapy of Non-Hodgkin's Lymphoma
Matthew D Pickford, J Harvey Turner
September-December 2012, 11(3):105-109
DOI:10.4103/1450-1147.103408  PMID:23372447
A Standard Operating Procedure (SOP) has been formulated for in-house preparation, quality control, dispensing and administration of 131 I-rituximab appropriate for the safe, effective, radioimmunotherapy of non-Hodgkin lymphoma. A decade of experience of semi-automated radioiodination of rituximab in our hospital radiopharmaceutical laboratory was analysed. The methodology was then refined for safe, practical, affordable application to radioimmunotherapy of lymphoma in departments of nuclear medicine in developing countries. This SOP has the potential to be incorporated into good laboratory practice conditions appropriate for local regulatory agency requirements.
  2 4,006 583
Warmth 7th International Conference on Radiopharmaceutical Therapy (Icrt 2012) Levi, Finland

September-December 2012, 11(3):117-117
  - 1,916 239
Pre-conference Symposium on Nuclear Cardiology

September-December 2012, 11(3):118-121
  - 1,718 193
ICRT-Speakers' Abstracts

September-December 2012, 11(3):121-153
  - 4,726 316
ICRT-Abstracts of Oral Presentations

September-December 2012, 11(3):154-159
  - 3,447 247
ICRT-Abstracts of Poster Presentations

September-December 2012, 11(3):160-200
  - 5,620 410
When was the Last Time You did Something for the First Time?
Ajit Kumar Padhy
September-December 2012, 11(3):99-100
DOI:10.4103/1450-1147.103404  PMID:23372444
  - 3,244 11,510
Nuclear Medicine in Finland
Kalevi Kairemo
September-December 2012, 11(3):101-102
DOI:10.4103/1450-1147.103406  PMID:23372445
  - 2,937 2,163
Global WARMTH for Patients with Cancer
J Harvey Turner
September-December 2012, 11(3):103-104
DOI:10.4103/1450-1147.103407  PMID:23372446
  - 2,452 1,984